Skip to main content

Day: August 3, 2020

Zealand Pharma Continues to Build Investor Relations and Communications Function with the Appointment of Mads Kronborg

Company announcement – No. 41 / 2020Zealand Pharma Continues to Build Investor Relations and Communications Function with the Appointment of Mads KronborgBringing more than a decade of corporate communications experience in the pharmaceutical industry, Kronborg will lead Investor Relations & Communication to further improve communication with investors, financial analysts, journalists and employees.Copenhagen, DK August 3, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company changing lives with innovative peptide-based medicines, today announced the appointment of Mads Kronborg as Head of Investor Relations & Communication, effective immediately. Mads brings more than a decade of corporate communication experience from his time at global pharmaceutical company, H. Lundbeck A/S, where he served...

Continue reading

Coloplast A/S – Transactions in connection with share buy-back programme, week 31

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.The following transactions have been executed during the period 27 – 31 July 2020:Henceforth, Coloplast owns 3,292,717 treasury B shares of DKK 1 equal to 1.52%...

Continue reading

Coloplast A/S – Transaktioner i henhold til aktietilbagekøbsprogram, uge 31

Som meddelt i Selskabsmeddelelse nr. 02/2020 har Coloplast iværksat et tilbagekøbsprogram på i alt 500 millioner kroner. Programmet begyndte den 24. februar 2020 og forventes afsluttet den 24. august 2020.Aktietilbagekøbsprogrammet struktureres i henhold til bestemmelserne i artikel 5 i EU-Parlamentet og Rådets forordning nr. 596/2014 af 16. april 2014 (MAR) og forordning 2016/1052, også kaldet ”Safe Harbour” reglerne, med det formål at opfylde forpligtelser i henhold til aktieoptionsprogrammer eller andre aktieallokeringer til medarbejdere eller at gennemføre en kapitalnedsættelse i henhold til artikel 5(2)(a) og artikel 5(2)(c) i MAR.I perioden 27. – 31. juli 2020 er der foretaget følgende køb:Coloplast ejer herefter 3.292.717 egne B-aktier à DKK 1 svarende til 1,52% af selskabets samlede aktiekapital.Separat oversigt med transaktionsdata...

Continue reading

NIO Inc. to Report Second Quarter 2020 Financial Results on Tuesday, August 11, 2020

SHANGHAI, China, Aug. 03, 2020 (GLOBE NEWSWIRE) — NIO Inc. (“NIO” or the “Company”) (NYSE: NIO), a pioneer in China’s premium smart electric vehicle market, today announced that it will report its second quarter 2020 unaudited financial results on Tuesday, August 11, 2020, before the open of the U.S. markets.The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 11, 2020 (8:00 PM Beijing/Hong Kong Time on August 11, 2020).Please register in advance of the conference using the link provided below and dial in 10 minutes prior to the call, using participant dial-in numbers, Direct Event passcode and unique registrant ID which would be provided upon registering.http://apac.directeventreg.com/registration/event/8596325Additionally, a live and archived webcast of the conference call will be...

Continue reading

cBrain har leveret sit første projekt til USDA

  Fondsbørsmeddelelse nr. 14/2020 cBrain har leveret sit første projekt til USDAKøbenhavn, 3. august 2020I november oplyste cBrain, at selskabet havde indgået aftale med en af myndighederne i den amerikanske centraladministration (Federal Government). cBrain kan nu med tilfredshed oplyse, at leverancen er afsluttet og godkendt af U.S. Department of Agriculture (USDA).Formålet med projektet har været at samle oplysninger på tværs af en række myndigheder med henblik på at hjælpe de amerikanske landmænd. Baseret på ny teknologi, og i samarbejde med en række partnere, er det således lykkedes at strømline og digitalisere information til brug for landmændenes arbejde.For IT-projekter gælder som regel, at en del af arbejdet udføres hos kunden. Men i forbindelse med dette projekt er det lykkedes at gennemføre det samlede projekt baseret på en...

Continue reading

cBrain has delivered its first project for USDA

  stock exchange announcement #14/2020 cBrain has delivered its first project for USDACopenhagen, August 3, 2020In November 2019, cBrain signed its first U.S. Government contract. cBrain is now pleased to announce that the project has been completed and accepted by the U.S. Department of Agriculture (USDA).The purpose of the project was to help bring together data from multiple agencies to help America’s farmers. Through the use of technology and the support of several partners, USDA has been able to deliver a streamlined digitized approach to information key to a farmer’s work.While IT projects regularly require on-site work, this project demonstrates how IT projects can be delivered solely based on a virtual organization. In this case including several government organizations and suppliers all working together.Best regardsPer Tejs...

Continue reading

Bilibili Announces Three-Year Strategic Partnership with Riot Games for Live Broadcasting League of Legend Events in China

SHANGHAI, China, Aug. 03, 2020 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (Nasdaq: BILI), a leading online entertainment platform for young generations in China, today announced its strategic partnership with Riot Games, the developer of leading MOBA League of Legends, among others, for granting Bilibili a three-year exclusive license for live broadcasting the League of Legend Esports (“LoL Esports”) global events (in Mandarin only), including the world-renowned League of Legend World Championship, Mid-Season Invitational, and All-Star Event in China beginning in 2020 through the 2023 Mid-Season Invitational.To mark the 10th anniversary of the League of Legend World Championship, Bilibili will join forces with Riot Games to host various online and offline esports events, bringing the world renowned, global tournament...

Continue reading

ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer

SINGAPORE, Aug. 03, 2020 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Kenneth Kobayashi has been appointed Chief Medical Officer. Dr Kobayashi will be based in California and will be responsible for the global clinical development of ASLAN’s pipeline, including the lead program, ASLAN004, an antibody that blocks the IL-13 receptor, which is being developed for atopic dermatitis (AD).Dr Kobayashi has more than 25 years of experience in drug development, clinical practice and regulatory affairs as a Dermatology expert. He most recently served as Senior Medical Director at Dermira, a subsidiary of Eli Lilly, where he was responsible for the development...

Continue reading

Turnover of Apranga Group in July 2020

The retail turnover (including VAT) of Apranga Group amounted to EUR 19.4 million in July 2020 and decreased by 4.5% compared to July 2019.In July 2020, the retail turnover of the Group in Lithuania remained at the level of the previous year, in Latvia decreased by 8.9% and in Estonia decreased by 12.1% year-to-year.In January through July 2020, the retail turnover of Apranga Group (including VAT) totalled EUR 106.2 million and decreased by 17.7% year-to-year.In January-July 2020, the retail turnover of Apranga Group in Lithuania decreased by 18.2% year-to-year, in Latvia decreased by 12.7% and in Estonia decreased by 22.8%.Currently Apranga Group operates the chain of 184 stores (106 in Lithuania, 51 in Latvia and 27 in Estonia) covering the gross area of 93.4 thousand sq. m., or by 5.5% more than a year ago.Saulius BačauskasApranga...

Continue reading

„Aprangos” grupės apyvarta 2020 m. liepos mėnesį

„Aprangos“ grupės tinklo mažmeninė prekių apyvarta (su PVM) 2020 m. liepos mėnesį sudarė 19,4 mln. eurų ir buvo 4,5% mažesnė nei 2019 m. liepos mėnesio apyvarta.Grupės tinklo apyvarta 2020 m. liepos mėnesį Lietuvoje išliko praeitų metų lygyje, Latvijoje sumažėjo 8,9%, o Estijoje apyvarta sumažėjo 12,1%, lyginant su 2019 metų liepos mėnesiu.2020 m. sausio-liepos mėnesiais „Aprangos“ grupės tinklo mažmeninė prekių apyvarta (su PVM) sudarė 106,2 mln. eurų, arba 17,7% mažiau nei 2019 metų atitinkamu laikotarpiu.„Aprangos“ grupės tinklo apyvarta 2020 m. sausio-liepos mėnesiais, lyginant su atitinkamu 2019 metų laikotarpiu, Lietuvoje sumažėjo 18,2%, Latvijoje sumažėjo 12,7%, o Estijoje apyvarta sumažėjo 22,8%.Šiuo metu „Aprangos“ grupė Baltijos šalyse valdo 184 parduotuvių tinklą (106 Lietuvoje, 51 Latvijoje ir 27 Estijoje), kurių bendras plotas...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.